Aurora Cannabis Hit with Securities Lawsuits


Nov. 25 2019, Published 10:43 a.m. ET

Recently, three law firms filed lawsuits against Aurora Cannabis (ACB) (ACB.TO). Kehoe Law Firm, Rosen Law Firm, and Bragar Eagel & Squire are currently investigating securities claims representing the buyers of Aurora Cannabis securities. These lawsuits are the result of accusations of misleading material statements by Aurora. The lawsuit demands the company compensate investors according to federal securities law.
Article continues below advertisement

The case against Aurora Cannabis

The investigation is mainly based on the question of whether Aurora Cannabis provided materially false and misleading statements to the public. It’s also accusing the company of not disclosing important unfavorable details about its plans and operations. When the news hit the market, Aurora stock plummeted, resulting in investor losses.
The specific allegations are as follows:
  • Aurora failed to disclose that its revenue would drop in the first quarter of fiscal 2020, which ended on September 30, 2019.
  • The company failed to disclose plans to stop the construction of its Aurora Sun and Aurora Nordic 2 facilities.
  • Due to this, the company’s statements about its receivables, operations, business, and future growth plans were materially incorrect and misleading.

The lawsuits represent investors that purchased the company’s securities from September 11, 2019, to November 14, 2019. The firms are attempting to gain compensation for investors under the Securities Exchange Act of 1934 to cover the damages they’ve suffered. The firms are also encouraging other investors to contact them to participate in the litigation.

Aurora’s statements

Aurora Cannabis recently announced its fiscal 2020 first-quarter results. The company reported 75.3 million Canadian dollars in revenue, a sequential decline of 24% from 98.9 million Canadian dollars in the fourth quarter of fiscal 2019. This result also included a 33% decline in the revenue of consumer cannabis products. The company also reported a greater EBITDA loss of 39.7 million Canadian dollars in the first quarter.

Aurora also announced its decision to delay its previously stated growth initiatives to cut expansion costs. Its construction at Denmark’s Aurora Nordic 2 and Canada’s Aurora Sun facilities have stopped for the foreseeable future, implying a decrease of 190 million Canadian dollars in capex. Aurora also announced that it was opening an early conversion privilege for convertible debenture holders. Holders currently have 230 million Canadian dollars’ worth of convertible debentures.

Aurora Cannabis stock

Though other cannabis stocks are tumbling this year, November has been rough for Aurora in particular. The stock has lost almost 25% of its value month-to-date. This drop is mainly the result of the quarterly results it reported in the second week of the month. From the time of its earnings release, the company’s stock has fallen 18%. Its peer Canopy Growth (CGC) (WEED) is also facing an investigation related to possible misleading statements.


More From Market Realist

    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.